Patient Area


12

2020

-

06

Recruitment Information: Expanded and Activated Lymphocytes [Ended]


On the last feasible date, EAL®The clinical trial has obtained approval from the ethics committees of 14 medical institutions. These institutions are located in Beijing, Tianjin, Henan, and Hebei, listed as follows:

General Hospital of the People's Liberation Army

Peking University People's Hospital

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences

Cancer Hospital, Chinese Academy of Medical Sciences

Beijing You'an Hospital, Capital Medical University

Beijing Cancer Hospital

Sixth Medical Center of the General Hospital of the People's Liberation Army

Fifth Medical Center of the General Hospital of the People's Liberation Army

Tianjin Cancer Hospital

Beijing Tiantan Hospital, Capital Medical University

Henan Cancer Hospital

First Hospital of Hebei Medical University

Fourth Hospital of Hebei Medical University

First Affiliated Hospital of Zhengzhou University

 

If you meet the following conditions:

Understand and voluntarily sign the informed consent form;

Aged 18 to 75 years, regardless of gender;

Patients with primary hepatocellular carcinoma;

According to the Guidelines for Diagnosis and Treatment of Primary Liver Cancer (2017 Edition) by the National Health and Family Planning Commission of the People's Republic of China, patients with clinical stages Ia to IIIa of liver cancer;

Child-Pugh score ≤ 7 points;

Have undergone radical resection for primary liver cancer (including open surgery or laparoscopic surgery);

Then you may meet the inclusion criteria for this study.